secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cadrenal Therapeutics, Inc. (CVKD)
CIK:        0001937993
Form:       8-K
Filed at:   2026-08-13T20:30:17+00:00
Accession:  0001213900-26-089147
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cadrenal Q2 net loss narrows to $3.3M; Phase 2 CAD-1005 cuts thrombotic events >25%
--------------------------------------------------------------------------------

- Q2 2026 net loss of $3.3M vs $3.7M in Q2 2025; R&D expenses $0.7M vs $1.1M; G&A $2.6M vs $2.7M.
- Cash ~$4.2M as of early August 2026, expected to fund operations through Q1 2027; not sufficient for clinical trials.
- Phase 2 CAD-1005 data at ISTH 2026 Congress in Paris showed >25% absolute reduction in thrombotic events.
- Launched structured partnering process for CAD-1005, frunexian, and tecarfarin; pursuing out-licensing model.
- Private placement raised ~$3.0M gross proceeds, up to ~$5.8M more if warrants fully exercised.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1937993/000121390026089147/0001213900-26-089147-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1937993/000121390026089147/ea0302042-8k_cadrenal.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-089147

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer